OCE Conversations on Cancer, Pazdur+25—Celebrating a Silver FDA Anniversary
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.
Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.
Patients, pathologists, clinicians, researchers, radiologists and others from around the world recently gathered for the 2024 International Invasive Lobular Carcinoma Symposium, in Leuven, Belgium.
The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.
Grzegorz S. Nowakowski, MD, discusses the methods and objectives of the part B expansion portion of the TakeAim Lymphoma study in patients with PCNSL.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Safety results and AE management approaches for talquetamab were reported by oncology nurses practicing at study sites participating in the MonumenTAL-1 studies.
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.
Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to…